desvenlafaxine extended release / Generic mfg. - LARVOL DELTA

Summer-pattern seasonal affective disorder: A case study and implications for primary care. (PubMed, JAAPA) - "In this article, a fictional, illustrative case report describes a 35-year-old woman with a 3-year pattern of summer depression meeting DSM-5-TR criteria for major depressive disorder with seasonal pattern, summer onset. In this case, treatment with desvenlafaxine, sleep/environmental modification, and CBT leads to significant improvement."

Journal • Anorexia • CNS Disorders • Depression • Insomnia • Major Depressive Disorder • Mood Disorders • Psychiatry • Psychomotor Agitation • Sleep Disorder

IDENTIFYING MEANINGFUL PATIENT SAVINGS ON GENERICS: DIRECT-TO-CONSUMER PRICES VS COMMERCIAL INSURANCE (ISPOR 2026) - "DTC pharmacies such as MCCPDC meaningfully lower out-of-pocket costs for higher-cost generic prescriptions which could otherwise be difficult to afford. Commercially insured patients should consider DTC pharmacies when their copayment or coinsurance for a generic medication exceeds $15, and particularly when it exceeds $100."

Clinical • Reimbursement • US reimbursement • CNS Disorders • Depression • Endocrine Disorders • Erectile Dysfunction • Multiple Sclerosis

The efficacy and safety of Desvenlafaxine Succinate Sustained-release Tablets in the prophylactic treatment of migraine (ChiCTR) - P=N/A | N=290 | Not yet recruiting | Sponsor: the Second Affiliated Hospital of Soochow University; the Second Affiliated Hospital of Soochow University

New trial • CNS Disorders • Migraine

Real-world effectiveness and tolerability of desvenlafaxine in major depressive disorder: A multicentre prospective Italian national-cohort study. (PubMed, Psychiatry Res) - "In this multicentre real-world cohort, desvenlafaxine was associated with substantial improvements in depressive and anxiety symptoms, increasing response and remission rates, favourable tolerability. These findings support desvenlafaxine as an effective and well-tolerated treatment option in routine clinical practice."

Journal • Real-world evidence • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Novel and promising treatments for anxiety disorders (WFSBP 2026) - "Results / Several compounds are in development, including drugs targeting the serotonin system (toludesvenlafaxine, gepirone, FKW00GA), the trace amine-associated receptor 1 (TAAR1), , the GABA binding site (ENX-102, darigabat, and buagafuran), the nicotinic receptor (soclenitant and VQW-765), the endocannabinoid system (cannabidiol and SYT-510), pherins (fasedienol) and psychedelics (MM120, PSX-001, MSP-1014). The translation of these compounds into clinically approved treatments for anxiety disorders may take several years, potentially delaying the emergence of significant therapeutic breakthroughs."

CNS Disorders • Mood Disorders • Psychiatry

Psychopharmacological Mechanisms of Antidepressant Withdrawal: Insights From Venlafaxine. (PubMed, Hum Psychopharmacol) - "Recognizing ADS as an intrinsic, predictable phase of chronic antidepressant pharmacotherapy-not an incidental complication or adverse effect-should guide informed consent, tapering practices, and future drug development. This narrative review examines ADS through pharmacological and neurobiological frameworks, using VEN to illustrate candidate mechanisms, clinical features, and risks."

Journal • Review • CNS Disorders • Psychiatry

Occurrence, temporal variation and environmental fate of psychoactive substances in wastewater treatment plant and receiving river | Poster Board #1509 (ACS-Fall 2026) - "Among antidepressants, venlafaxine, desvenlafaxine and amisulpride were the dominant compounds, with mean concentrations 575.98, 532.03 and 490.85 ng/L. Sulpiride and amisulpride were the main antipsychotic drugs...The consumption pattern of methamphetamine, MDA, ketamine and codeine shows a significant weekend effect. In the downstream receiving river, the concentrations of most PSs showed a decreasing trend with increasing distance from the WWTP effluent, whereas the concentrations of norketamine, benzoylecgonine and desvenlafaxinesome increased, indicating that bio-transformation and abiotic transformation processes occurred during the transport of pollutants in the aquatic environment."

CNS Disorders

Possible desvenlafaxine associated hypoglycemia in an adult woman with major depressive disorder. (PubMed, Asian J Psychiatr) - No abstract available

Journal • CNS Disorders • Depression • Hypoglycemia • Major Depressive Disorder • Mood Disorders • Psychiatry

Toludesvenlafaxine for Non-specific Low Back Pain (clinicaltrials.gov) - P=N/A | N=132 | Recruiting | Sponsor: Beijing Tiantan Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Pain

Evaluating Caenorhabditis elegans as a Toxicity Model for Reuptake Inhibitors. (PubMed, MicroPubl Biol) - "Escitalopram showed greater toxicity than citalopram, duloxetine was more toxic than milnacipran, and desvenlafaxine, but not venlafaxine, produced toxicity. These results suggest that C. elegans cannot replace mammalian testing, but may serve as a rapid and low-cost prescreening model."

Journal

Exploratory Study of Pharmacogenomic Biomarkers for Toludesvenlafaxine (ChiCTR) - P=N/A | N=200 | Not yet recruiting | Sponsor: Affiliated Kangning Hospital of Ningbo University; Affiliated Kangning Hospital of Ningbo University

Biomarker • New trial • CNS Disorders • Depression • Mood Disorders • Psychiatry

Toludesvenlafaxine for Non-specific Low Back Pain (clinicaltrials.gov) - P=N/A | N=132 | Not yet recruiting | Sponsor: Beijing Tiantan Hospital

New trial • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Pain

Extended-release naltrexone (Vivitrol) augmentation for compulsive sexual behavior disorder: a case report. (PubMed, Ir J Psychol Med) - "This case suggests extended-release naltrexone may be an effective augmentation strategy for CSBD unresponsive to antidepressant pharmacotherapy and psychotherapy. Controlled trials are needed to establish efficacy."

Journal • Behavior Disorders • CNS Disorders • Mental Retardation • Psychiatry • Substance Abuse

A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder. (clinicaltrials.gov) - P3 | N=555 | Completed | Sponsor: Luye Pharma Group Ltd. | Recruiting ➔ Completed | Trial completion date: Apr 2026 ➔ Jul 2025 | Trial primary completion date: Apr 2026 ➔ Jul 2025

Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • General Anxiety Disorder • Mood Disorders • Psychiatry

Desvenlafaxine as a Potential First-Line Treatment for Major Depressive Disorder: A Comprehensive Review and Consensus-Based Clinical Perspective on Efficacy, Safety and Patient Selection Profiles. (PubMed, Clin Drug Investig) - "In addition, its predictable pharmacokinetics make it a practical choice in primary care settings. While most current guidelines typically recommend selective serotonin reuptake inhibitors as first-line treatment, the favourable tolerability profile and efficacy of desvenlafaxine across diverse symptom clusters may support its consideration as a first-line option in select patient populations."

Journal • Review • CNS Disorders • Cognitive Disorders • Depression • Fatigue • Major Depressive Disorder • Mood Disorders • Psychiatry

Intranasal esketamine in treatment-resistant bipolar depression maintained on long-acting aripiprazole (CINP 2026) - " Case 1: A 30-year-old female with bipolar disorder was maintained on a monthly aripiprazole injection of 400 mg since June 2024 in combination with clomipramine 150mg, quetiapine 300mg, and lisdexamfetamine 30mg...Case 2: A 21-year-old female with bipolar disorder was maintained on a monthly aripiprazole injection 400 mg since February 2025 in combination with lithium 400 mg, lamotrigine 400mg, Zyprexa 10 mg, and bupropion 300mg...Case 3: A 31-year-old male with bipolar disorder was maintained on a monthly aripiprazole injection of 400 mg since May 2024in combination with desvenlafaxine 150mg...Case 4: A 38-year-old female with bipolar disorder was maintained on a monthly aripiprazole injection of 400 mg since July 2025 in combination with escitalopram 20 mg, Wellbutrin 300 mg, and lithium 400 mg. These cases demonstrated that there may be a role for adding intranasal esketamine in treatment-resistant bipolar depression in patients already maintained on monthly..."

Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Desvenlafaxine in the treatment of major depressive disorder (CINP 2026) - "Background: Desvenlafaxine is the active metabolite of Venlafaxine (Desmethylvenlafaxine) and acts at a lower dose as a selective serotonin reuptake inhibitor. Desvenlafaxine is the new therapeutic challenge for the treatment of major depression and is added to the therapeutic quiver."

CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Antidepressant efficacy in children and adolescents: a comprehensive patient-level item-based meta-analysis (CINP 2026) - "Aims & Objectives: Based on 22 double-blind placebo-controlled clinical trials (n=5,496) of SSRIs (citalopram, escitalopram, fluoxetine, sertraline, paroxetine) and SNRIs (desvenlafaxine, duloxetine, venlafaxine), most of which used the Children's Depression Rating Scale (CDRS-R) for assessment of outcome, this study was undertaken to shed light on antidepressant responsiveness in those aged 18 or below with special focus on the possible impact of age (6-11 vs 12-14 vs 15-18) and sex. It is concluded i) that age and sex – and tentatively puberty – are strong predictors for the antidepressant effect of SSRIs in subjects aged ≤18 years, the effect being weakest in boys below the age of 11 and largest in subjects of both sexes above the age of 15, ii) that significant differences between active drug and placebo – when at hand – are often observed already at the first week of treatment, iii) that the previous suggestion that fluoxetine be superior to other SSRIs in..."

Retrospective data • CNS Disorders • Depression

Analysis of ocular adverse events associated with SNRIs. (PubMed, Front Pharmacol) - "This study aimed to investigate and compare the safety signals of ocular adverse events (AEs) associated with five major SNRIs (venlafaxine, duloxetine, desvenlafaxine, milnacipran, and levomilnacipran). Based on real-world data, this study identified drug-specific and sex-specific differences in the ocular safety signals of SNRIs. Mydriasis represents a common strong risk signal across multiple SNRIs."

Adverse events • Journal • CNS Disorders • Mental Retardation • Ophthalmology • Pain • Psychiatry

OPTION-VMS: A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats (clinicaltrials.gov) - P=N/A | N=999 | Completed | Sponsor: Astellas Pharma Global Development, Inc. | Active, not recruiting ➔ Completed

Real-world evidence • Trial completion

Effects of antidepressant medications on brain tissue microstructure in persistent depressive disorder across two randomized controlled trials. (PubMed, Neuroimage Clin) - P4 | "Medication may have reduced the need for compensatory response because it reduces symptom severity, whereas placebo sustains the need for compensation. The unique and common effects of duloxetine and desvenlafaxine on neurotransmitter systems are likely responsible for their spatially unique and common effects in altering tissue microstructure."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Venlafaxine reverses chemotherapy-induced alopecia through epithelial and dermal reprogramming at single-cell resolution. (PubMed, Biomed Pharmacother) - "Cyclophosphamide treatment induces profound suppression of ribosomal biogenesis, cytoplasmic translation, mitochondrial oxidative phosphorylation, and Wnt-associated regenerative programs in hair matrix cells, indicating a functional metabolic arrest preceding overt epithelial cell loss...Topical venlafaxine and its active metabolite desvenlafaxine preserved follicular architecture, suppressed apoptosis, and restored hair shaft elongation in both mouse CIA models and human hair follicle organ culture. At single-cell resolution, venlafaxine reversed epithelial translational shutdown, reactivated differentiation and Wnt signaling programs, and attenuated fibroinflammatory remodeling, thereby restoring paracrine niche signaling and matrix cell proliferation. Collectively, these findings redefine CIA as a disorder characterized by coordinated epithelial functional arrest and dermal inflammatory remodeling and identify venlafaxine as a potential pharmacological strategy to..."

Journal • Alopecia • Immunology • Oncology • FGF10 • FGF7 • IL6 • SLIT2

Episode duration and severity as predictors of placebo response in major depressive disorder. (PubMed, J Affect Disord) - "Chronicity and severity were unrelated; both variables were associated with lower placebo response rates, but neither moderated the efficacy of desvenlafaxine over placebo, as evidenced by nonsignificant subgroup-treatment interactions. Overall, the results suggest that chronicity and severity are general prognostic indicators and did not support the notion that drug-placebo differences could be meaningfully increased by selectively recruiting clinical trial participants based on these criteria."

Clinical • Journal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

NBOLD: Predictors of Cognitive Outcomes in Geriatric Depression (clinicaltrials.gov) - P4 | N=75 | Active, not recruiting | Sponsor: David Steffens | Trial completion date: Jun 2026 ➔ Apr 2027 | Trial primary completion date: Jun 2026 ➔ Apr 2027

Trial completion date • Trial primary completion date • CNS Disorders • Depression • Geriatric Disorders • Major Depressive Disorder • Mood Disorders • Psychiatry

An Individual Participant Data Analysis: Optimizing Pharmacological Treatment in Children and Adolescents With Major Depressive Disorder. (PubMed, J Am Acad Child Adolesc Psychiatry) - "These findings advance a preliminary understanding of the precision medicine framework for pediatric MDD, indicating that individual characteristics (age, sex, ethnicity, BMI, symptom severity, family history) may influence treatment outcomes. Exploratory subgroup analyses suggest fluoxetine's efficacy may be more pronounced in certain populations: children, female participants, White individuals, healthy weight participants, and those with severe symptoms. These findings require validation in diverse cohorts. Universal suicide-related outcome assessment across all subgroups (regardless of individual characteristics) remains essential. The study advocates for regulatory reforms to promote subgroup analysis reporting in clinical trials, consistent with emerging precision psychiatry initiatives."

Journal • CNS Disorders • Depression • Major Depressive Disorder • Mental Retardation • Mood Disorders • Pediatrics • Psychiatry